Results 121 to 130 of about 3,281,120 (365)
JCPP Advances, EarlyView.Abstract Background This study aims to evaluate the clinical value of using QbCheck in routine Attention Deficit Hyperactive Disorder (ADHD) clinics by investigating longitudinal inter‐domain relationships between objective neurocognitive outcomes of QbCheck and subjective clinical outcomes: ADHD core symptoms, impairment and quality of life (QoL ...
Seungjae Lee +3 more
wiley +1 more source
Acute dystonia induced by quetiapine: a case report
Open Journal of Psychiatry and Allied Sciences, 2015 Quetiapine is an atypical antipsychotic which has been shown to have lower incidence of extrapyramidal symptoms (EPS). In recent times, few case reports and case series have reported occurrence of akathisia, dystonia, and Parkinsonism with quetiapine ...
Sachin Ratan Gedam, Santanu Ghosh
doaj
Farmeconomia: Health Economics and Therapeutic Pathways, 2011 Objective: to comparatively investigate – by means of computer simulations – the economic cost and clinical outcomes of five atypical oral antipsychotic agents (ziprasidone, olanzapina, risperidone, paliperidone and aripiprazolo).
Andrea Fagiolini +4 more
doaj +1 more source
Archives of General Psychiatry, 2005 BACKGROUND While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or ...
D. Henderson +11 more
semanticscholar +1 more source
Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]
Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank +2 more
core
Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response [PDF]
, 2011 Background: Selective serotonin reuptake inhibitors take several weeks to achieve their full antidepressant effects. Post-synaptic 5-HT<sub>2A</sub> receptor activation is thought to be involved in this delayed therapeutic effect ...
A. F. Schatzberg +14 more
core +1 more source
Control of seizures in a clozapine-treated schizophrenia patient, using valproate: a case report
Psychiatry and Clinical Psychopharmacology, 2019 Schizophrenia is characterized by an adverse clinical course and poor psychosocial functioning, and causes problems in the social-cognitive sphere.
Hamza Ayaydın, Şermin Bilgen Ulgar
doaj +1 more source
Clinical applications of personalized medicine: a new paradigm and challenge [PDF]
, 2017 The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease.
Borro, Marina +7 more
core +1 more source
Pharmacists in aged care: outcomes of a national stakeholders meeting
Journal of Pharmacy Practice and Research, EarlyView.Abstract Background Medicine safety is a critical concern for Australia's growing aged‐care population. Pharmacists play a vital role in improving medicines management, but their integration into aged‐care settings requires careful planning. Aim To report on the outcomes of a national meeting of stakeholders in Australia exploring the integration of ...
Kate Wang +10 more
wiley +1 more source
The phytocannabinoid, Δ(9) -tetrahydrocannabivarin, can act through 5-HT1 A receptors to produce antipsychotic effects [PDF]
, 2015 Funded by: •GW Pharmaceuticals Acknowledgements: The authors wish to thank Mrs Lesley Stevenson for technical support and Dr John Raymond, Dr Keith Parker and Dr Ethan Russo for providing human 5-HT1A CHO cells.
Cascio, Maria Grazia +4 more
core +1 more source